anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-23 and is reviewed periodically as new material appears.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
where quantities in square brackets represent the molar concentrations of the species at equilibrium. For example, a hypothetical weak acid having Ka = 10−5, the value of log Ka is the exponent (−5), giving pKa = 5. For acetic acid, Ka = 1.8 x 10−5, so pKa is 4.7. A lower Ka corresponds to a weaker acid (an acid that is less dissociated at equilibrium). The form pKa is often used because it provides a convenient logarithmic scale, and a lower pKa corresponds to a stronger acid.
Conscious proprioception is communicated by the dorsal column-medial lemniscus pathway to the cerebrum. Nonconscious proprioception is communicated primarily via the dorsal spinocerebellar tract and ventral spinocerebellar tract, to the cerebellum. A nonconscious reaction is seen in the human proprioceptive reflex, or righting reflex—in the event that the body tilts in any direction, the person will cock their head back to level the eyes against the horizon. This is seen even in infants as soon as they gain control of their neck muscles. This control comes from the cerebellum, the part of the brain affecting balance.
=== Desalination/ion separation === MOF membranes can achieve substantial ion selectivity due to their small repeating structures. This offers the potential for use in desalination and water treatment. As of 2020, reverse osmosis supplied more than two-thirds of global desalination capacity, and the last stage of most water treatment processes. Osmosis does not use dehydration of ions, or selective ion transport in biological channels and it is not energy efficient. The mining industry uses membrane-based processes to reduce water pollution, and to recover metals. MOFs could be used to extract metals such as lithium from seawater and waste streams. MOF membranes such as ZIF-8 and UiO-66 membranes with uniform subnanometer pores consisting of angstrom-scale windows and nanometer-scale cavities displayed ultrafast selective transport of alkali metal ions. The windows acted as ion selectivity filters for alkali metal ions, while the cavities functioned as pores for transport. The ZIF-8 and UiO-66 membranes showed a LiCl/RbCl selectivity of ~4.6 and ~1.8, respectively, much higher than the 0.6 to 0.8 selectivity in traditional membranes. A 2020 study suggested that a new MOF called PSP-MIL-53 could be used along with sunlight to purify water in just half an hour.
Sources: en.wikipedia.org
Worldwide weather conditions during the flight were extremely favorable with most of the regions of the Earth the spacecraft passed over dominated by high pressure zones—in the three previous flights, only the Western Sahara and Southwestern United States were reliably cloudless. Nonetheless, haze and air pollution impeded visibility for Cooper—despite passing over Los Angeles and Calcutta, he could see neither city due to smog. At the start of the 17th orbit while crossing Cape Canaveral, Florida, Cooper transmitted slow scan black and white television pictures to Mercury Control. The picture showed a ghostly image of the astronaut. In the murky picture, a helmet and hoses could be seen. It was the first time an American astronaut had sent back television images from space. On the 17th and 18th orbits, Cooper took infrared weather photos and moonset Earth-limb pictures. He also resumed Geiger counter measurements of radiation. He sang during orbits 18 and 19, and marveled at the greenery of Earth. It was nearing 30 hours since liftoff.
During long-term use, labetalol can reduce heart rate during exercise while maintaining cardiac output by an increase in stroke volume. Labetalol possesses significant intrinsic sympathomimetic activity (ISA). In particular, it is a partial agonist at β2-adrenergic receptors located in the vascular smooth muscle. Labetalol relaxes vascular smooth muscle by a combination of this partial β2-adrenergic receptor agonism and through α1-adrenergic receptor blockade. Overall, this vasodilatory effect can decrease blood pressure. It was originally reported to lack ISA, but a slight degree of activity was subsequently characterized. Similar to local anesthetics and sodium channel blocking antiarrhythmics, labetalol also has membrane stabilizing activity. By decreasing sodium entry, labetalol decreases action potential firing and thus has local anesthetic activity.
== Incarceration == Initially Rose was incarcerated at HM Prison Bronzefield, Middlesex, as a Category A prisoner. She was transferred to HM Prison Low Newton in County Durham in 2008. It was reported in May 1995 that Rose and Myra Hindley—who were both incarcerated in HM Prison Durham at the time (Rose was on remand)—had formed a "friendship". Hindley denied the claims as "nonsense". Rose acknowledged that they knew each other from being on the same wing but denied further speculation that the two were "having an affair". Both of Rose's eldest biological children, and her stepdaughter, Anna Marie, initially visited her in prison on a regular basis, although by 2006 she had ceased contact with them after Mae began asking questions about her culpability in the murders. Rose justified her decision with the explanation: "I was never a parent [then] and could never be now." In 2019 Rose was transferred to HM Prison New Hall in West Yorkshire. It was reported the transfer had taken place after serial killer Joanna Dennehy, who had just been transferred to Low Newton, had threatened to kill Rose, although official sources stated that the reports were untrue.
== Further reading == Cimaz, Rolando (2016). "Systemic-onset juvenile idiopathic arthritis". Autoimmunity Reviews. 15 (9): 931–934. doi:10.1016/j.autrev.2016.07.004. PMID 27392503. Mellins, Elizabeth D.; Macaubas, Claudia; Grom, Alexei A. (2011). "Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions". Nature Reviews Rheumatology. 7 (7): 416–426. doi:10.1038/nrrheum.2011.68. ISSN 1759-4790. PMC 4180659. PMID 21647204.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.